|
Çѱ¹MSD À¯ÇÑȸ»ç |
CRA ´Ù¼ö ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
2³â¡è |
ä¿ë½Ã |
08.05 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)CRA ´Ù¼ö ¸ðÁý
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
2³â¡è |
ä¿ë½Ã |
05.21 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
[Çѱ¹MSD]Business practice officer(Compliance officer)
¼¿ï Áß±¸, ¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
À繫/ȸ°è/IR/ÀÚ±Ý/°¨»ç |
2³â¡è |
ä¿ë½Ã |
05.10 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)RA Specialist 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
05.13 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Oncology MSL 2¸í ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
10.31 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA ´Ù¼ö ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
09.04 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
Çѱ¹MSD CRA 0¸í ä¿ë
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) ÀçÇÐ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
05.10 |
|
|
(ÁÖ)¾¾¾Ø¾¾ÇコÄɾî |
¾¾¾Ø¾¾ÇコÄÉ¾î ¿µ¾÷ºÎ Á¦¾à¿µ¾÷(¼¿ï°æ±âÁö¿ª) Á¤±ÔÁ÷ Ãß°¡
¼¿ï ÀüÁö¿ª, °æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
09.17 |
|
|
Çѱ¹MSD À¯ÇÑȸ»ç |
(Sr.)CRA ä¿ë
¼¿ï Áß±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
07.24 |
|
|
Çѱ¹Organon |
Çѱ¹Organon-Market Access Specialist 1¸í ¸ðÁý
¼¿ï Á¾·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
12.04 |
|
|
PSI CRO Korea |
[PSI CRO Korea] SSU Associate
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
05.04 |
|
|
¾È±¹¾àÇ°(ÁÖ) |
¾È±¹¾àÇ°(ÁÖ) Á¾ÇÕº´¿ø»ç¾÷ºÎ MR ¸ðÁý(°æ·Â)
´ëÀü ÀüÁö¿ª, Ãæ³² ÀüÁö¿ª, ÃæºÏ ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
04.29 |
|
|
Çѱ¹MSD ÁÖ½Äȸ»ç |
ID/Vaccine MSL ¸ðÁý
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
Çмú/±³À°/»ó´ã |
2³â¡è |
ä¿ë½Ã |
03.11 |
|
|
(ÁÖ)´ë¿õ¹ÙÀÌ¿À |
[´ë¿õ¹ÙÀÌ¿À] °øÁ¤¾ÈÀü°ü¸®(¾ÈÀü°ü¸®ÀÚ) °æ·Â»ç¿ø ä¿ë
°æ±â ȼº½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
»ý»ê/»ý»ê°ü¸® |
2³â¡è |
ä¿ë½Ã |
01.18 |
|
|
¿¥¾ÆÀ̾ËȦµù½º |
¿Ü±¹°è ÇコÄɾî-Research Analyst
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
04.22 |
|